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Abstract: 
Neurocritical care depends, in part, on careful patient monitoring but as yet there are little data on what 
processes are the most important to monitor, how these should be monitored, and whether monitoring 
these processes is cost effective and impacts outcome. At the same time, bio-informatics is a rapidly 
emerging field in critical care but as yet there is little agreement or standardization on what information 
is important and how it should be displayed and analyzed. The Neurocritical Care Society (NCS) in 
collaboration with the European Society of Intensive Care Medicine (ESICM), the Society for Critical Care 
Medicine (SCCM) and the Latin America Brain Injury Consortium (LABIC) organized an international, 
multidisciplinary consensus conference to begin to address these needs. International experts from 
neurosurgery, neurocritical care, neurology, critical care, neuroanesthesiology, nursing, pharmacy and 
informatics were recruited based on their research, publication record and expertise. They undertook a 
systematic literature review to develop recommendations about specific topics on physiologic processes 
important to the care of patients with disorders that require neurocritical care. This review does not 
make recommendations about treatment, imaging and intraoperative monitoring. A multidisciplinary 
jury, selected for their expertise in clinical investigation and development of practice guidelines, guided 
this process. The GRADE system was used to develop recommendations based on literature review, 
discussion, integrating the literature with the participants’ collective experience and critical review by an 
impartial jury. Emphasis was placed on the principle that recommendations should be based on both 
data quality and on tradeoffs and translation into clinical practice. Strong consideration was given to 
providing pragmatic guidance and recommendations for bedside neuromonitoring, even in the absence 
of high quality data. 
Key words: consensus development conference, Grading of Recommendations Assessment, 
Development and Evaluation (GRADE), brain metabolism, brain oxygen; clinical trials, intracranial 
pressure, microdialysis; multimodal monitoring; neuromonitoring, traumatic brain injury, brain 
physiology, bio-informatics, biomarkers, neurocritical care, clinical guidelines. 
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Introduction: 
The Neurocritical Care Society (NCS) in collaboration with the European Society of Intensive Care 
Medicine (ESICM), the Society for Critical Care Medicine (SCCM) and the Latin America Brain Injury 
Consortium (LABIC) commissioned a consensus conference on monitoring patients with acute 
neurological disorders that require intensive care management.  
Patient monitoring using some, many, or all of the techniques outlined in this consensus document is 
routinely performed in most Neurocritical Care Units (NCCU) on patients with acute neurological 
disorders who require critical care. In many institutions the combined use of multiple monitors is 
common, a platform often termed “multimodality monitoring” (MMM). The use of such tools to 
supplement the clinical examination is predicated by the insensitivity of the neurologic examination to 
monitor for disease progression in patients in whom the clinical features of disease are confounded by 
the effects of sedation, analgesia and neuromuscular blockade, or in deeply comatose patients (e.g. 
malignant brain edema, seizures, and brain ischemia) where neurological responses approach a 
minimum and become insensitive to clinical deterioration. Several considerations frame our subsequent 
discussion: 
1. As with general intensive care, basic monitoring such as electrocardiography, pulse oximetry
and blood pressure supports the management of critically ill neurological patients. The use of
these monitoring modalities has become routine despite limited Level I evidence to support
their use. It is not our intention to make recommendations for such monitoring, except where
such recommendations are directly relevant to clinical care of the injured or diseased nervous
system.
2. We accept that imaging is indispensable in the diagnosis and management of the critically ill
patient with neurological disease, perhaps more so than any other area of intensive care
medicine. However, with a few exceptions we have elected not to focus on imaging but rather
will concentrate on bedside tools that can be used in the intensive care unit (ICU).
3. It is not our intent to discuss or recommend therapy in any of the settings we address. This may
seem to be a somewhat arbitrary distinction, but the distinction allows us to focus our questions
on the act of monitoring rather than the act of treatment. It must be recognized that no monitor
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in the end will change outcome. Instead it is how that information is interpreted and integrated 
into clinical decision-making and then how the patient is treated that will influence outcome. 
For many of the processes monitored, effective treatments have still to be fully elucidated or 
remain empiric rather than mechanistic. In this context, monitoring can be valuable in learning 
about pathophysiology after acute brain injury and potentially help identify new therapies. 
4. The purpose of this consensus document is to provide evidence-based recommendations about
monitoring in neurocritical care patients, and to base these recommendations on rigorously
evaluated evidence from the literature. However, we also recognize that, in many cases, the
available evidence is limited for several reasons:
a. Some monitors have strong anecdotal evidence of providing benefit, and formal
randomized evaluation is limited by real or perceived ethical concerns about
withholding potentially life-saving monitors with an outstanding safety record.
b. Important physiological information obtained from several monitors may translate into
outcome differences in select patients, but this benefit is not universal and is diluted by
the patients in whom such effects are not seen. However, we still do not have a clear
basis for identifying the cohorts in whom such benefit should be assessed.
c. The process by which we identify treatment thresholds based on monitoring, and the
process to integrate multiple monitors is still being elucidated.
5. The monitoring tools we discuss fall into several categories, and their nature and application
predicates how discussion of their utility is framed. Some of these tools (e.g. intracranial
pressure [ICP], brain oximetry, and microdialysis) meet the definition of bedside monitors, and
are assessed in terms of their accuracy, safety, indications, and impact on prognostication,
management and outcome. However, other tools (e.g. biomarkers and tests of hemostasis) are
used intermittently, and are best dealt with in a different framework. Our choice of review
questions addresses this difference.
6. In addition to the discussion of individual monitors we also include some correlative essays on
the use of monitoring in emerging economies, where we attempt to identify how our
recommendations might be applied under conditions where there are limited resources. This
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discussion also provides a useful framework for minimum standards of monitoring and 
assessment of the effects in a wider conversation.  
7. This issue also includes two other correlative essays. One focuses on metrics for processes and
quality of care in neurocritical care that provides an organizational context for the
recommendations that we make. Finally, we provide a separate discussion on the integration of
multimodality monitoring, which draws on the rapid advances in bioinformatics and data
processing currently available. In each of these cases we recognize that the field is currently in a
state of flux, but have elected to provide some recommendations in line with the data currently
available.
8. The intent of this consensus statement is to assist clinicians in decision-making. However, we
recognize that this information must be targeted to the specific clinical situation in individual
patients, based on clinical judgment and resource availability. We therefore recognize that,
while our recommendations provide useful guidance, they cannot be seen as mandatory for all
individual clinician-patient interactions.
Given this background, and recognizing the clinical equipoise for most of the brain monitors that will be 
discussed, we assess basic questions about monitoring patients with acute brain disorders who require 
critical care. Our recommendations for monitoring are based on a systematic literature review, a robust 
discussion during the consensus conference about the interpretation of the literature, the collective 
experience of the members of the group and review by an impartial, international jury. 
Process 
A fundamental goal in the critical care management of patients with neurological disorders is 
identification, prevention and treatment of secondary cerebral insults that are know to exacerbate 
outcome. This strategy is based on a variety of monitoring techniques that includes the neurological 
examination, imaging, laboratory analysis and physiological monitoring of the brain and other organ 
systems used to guide therapeutic interventions. The reasons why we monitor patients with 
neurological disorders are listed in Table 1. In addition rather than focus on individual devices we chose 
to review physiological processes that are important to neurocritical care clinicians (Table 2). Each of 
these topics is further reviewed in individual chapters contained in this supplement. The reader is 
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referred to these chapters for further details about the review process, evidence to support the 
recommendations in this summary document and additional citations for each topic. 
Table 1: Reasons why we monitor patients with neurologic disorders who require critical care 
Table 2: Physiological processes that are important to neurocritical care clinicians that were selected 
for review in the International Multidisciplinary Consensus Conference on Multimodality Monitoring 
in Neurocritical Care 
Topic Section 
Clinical Evaluation 
Systemic Hemodynamics 
Intracranial Pressure and Cerebral Perfusion Pressure 
Cerebrovascular Autoregulation 
Systemic and Brain Oxygenation 
Cerebral Blood Flow and Ischemia 
Electrophysiology 
Cerebral Metabolism 
Glucose and Nutrition 
Hemostasis and Hemoglobin 
Temperature and Inflammation 
Biomarkers of Cellular Damage and Degeneration 
ICU Processes of Care 
Multimodality Monitoring Informatics Integration, Display and Analysis 
• Detect early neurological worsening before irreversible brain damage occurs
• Individualize patient care decisions
• Guide patient management
• Monitor the physiologic response to treatment and to avoid any adverse effects
• Allow clinicians to better understand the pathophysiology of complex disorders
• Design and implement management protocols
• Improve neurological outcome and quality of life in survivors of severe brain injuries
• Through understanding disease pathophysiology begin to develop new mechanistically oriented
therapies where treatments currently are lacking or are empiric in nature
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Monitoring in Emerging Economies 
Future Directions and Emerging Technologies 
The GRADE system classifies recommendations as strong or weak, according to the balance among 
benefits, risks, burden, and cost, and according to the quality of evidence. Keeping those components 
separate constitutes a crucial and defining feature of this grading system. An advantage of the GRADE 
Representatives of the NCS and ESICM respectively chaired the review and recommendation process. 
Experts from around the world in the fields of neurosurgery, neurocritical care, neurology, critical care, 
neuroanesthesiology, nursing, pharmacy and informatics were recruited based on their expertise and 
publication record related to each topic. Two authors were assigned to each topic and efforts were 
made to ensure representation from different societies, countries and disciplines (Appendix 1). The 
review and recommendation process, writing group and topics were reviewed and approved by the NCS 
and ESICM. A jury of experienced neurocritical care clinicians (physicians, a nurse and a pharmacist) was 
selected for their expertise in clinical investigation and development of practice guidelines.  
The authors assigned to each topic performed a critical literature review with the help of a medical 
librarian according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement (1). The review period included January 1980 - September 2013 and was limited to 
clinical articles that included more than 5 subjects and were published in English. The focus was on adult 
patients and brain disorders. The literature findings were summarized in tables and an initial summary 
that included specific recommendations was prepared. The chairs, co-chairs and jury members, each 
assigned to specific topics as a primary or secondary reviewer, reviewed these drafts. The quality of the 
data was assessed and recommendations developed using the GRADE system [2-10]. The quality of the 
evidence was graded as: 
 High = Further research is very unlikely to change our confidence in the estimate of effect.
 Moderate = Further research is likely to have an important impact on our confidence in the
estimate of effect and may change the estimate.
 Low = Further research is very likely to have an important impact on our confidence in the
estimate of effect and is likely to change the estimate.
 Very low = Any estimate of effect is very uncertain.
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system is that it allows for strong recommendations in the setting of lower quality evidence and 
therefore is well suited to the intended monitoring questions. Recommendations are stated as either 
strong (“we recommend”) or weak (“we suggest”) and based on the following: 
 The trade-offs, taking into account the estimated size of the effect for the main outcomes, the
confidence limits around those estimates, and the relative value placed on each outcome,
 Quality of the evidence, and
 Translation of the evidence into practice in a specific setting, taking into consideration
important factors that could be expected to modify the size of the expected effects.
Each topic was then presented and discussed at a 2-day conference in Philadelphia held on September 
29 and 30, 2013. The chairs, co-chairs, jury and each author attended the meeting. In addition 
representatives from each of the endorsing organizations were invited and 50 additional attendees with 
expertise in neurocritical care were allowed to register as observers. Industry representatives were not 
allowed to participate. Each author presented a summary of the data and recommendations to the jury 
and other participants. Presentations were followed by discussion focused on refining the proposed 
recommendations for each topic. Approximately 1/3 of the conference time was used for discussion. 
The jury subsequently held several conference calls, and then met again at a subsequent two-day 
meeting to review and abstract all manuscripts and finalize the summary consensus statement 
presented here. They reviewed selected key studies, the recommendations made by the primary 
reviewers and the discussion that took place at the conference. Strong consideration was given to 
providing guidance and recommendations for bedside neuromonitoring, even in the absence of high 
quality data. 
Caveats and limitations to the process: The setting of these recommendations, monitoring, makes it 
difficult to use all of the normal considerations used to make decisions about the strength of 
recommendations, typically of a treatment (4), which include the balance between desirable and 
undesirable effects, estimates of effect based on direct evidence, and resource use since monitoring has 
no proximate effects on outcome. Instead it typically modifies treatment and can only influence 
outcome through such modulation. Our confidence in the estimate of effects in most analyses was not 
derived from methodologically rigorous studies, because few such studies exist, but often driven by 
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epidemiological studies and investigations of clinical physiology, which usually provided indirect 
evidence, with several potential confounders. 
Given these limitations, decisions on recommendations are driven by an expectation of values and 
preferences. Given the limited outcome data of both benefit and harm associated with 
neuromonitoring, we relied on inferences from observational studies and extrapolation from 
pathophysiology to estimate the effect and effect size of potential benefit and harm. We concluded that 
the avoidance of permanent neurological deficit would be the dominant driver of patient choice. Given 
that the diseases and disease mechanisms we monitor are known to be damaging, and given that the 
time available for intervention is limited, we made these extrapolations unless there was real concern 
about benefit or evidence of harm.  This approach to deciding on recommendations was universally 
adopted by all members of the multispecialty, multidisciplinary, multinational panel. Though there was 
some variation in initial opinions, careful consideration of the available evidence and options resulted in 
relatively tightly agreed consensus on recommendations.  
SUMMARY OF RECOMMENDATIONS FROM THE INDIVIDUAL CONSENSUS CONFERENCE TOPICS 
Clinical Evaluation 
Questions addressed 
1. Should assessments with clinical coma scales be routinely performed in comatose adult patients
with acute brain injury?
2. For adult comatose patient with acute brain injury, is Glasgow Coma Scale (GCS) or the Full Outline
of Unresponsiveness (FOUR) score more reliable in the clinical assessment of coma?
3. Which pain scales have been validated and shown to be reliable among patients with brain injuries
who require neurocritical care?
4. Which pain scales have been validated and shown to be reliable among patients with severe
disorders of consciousness (minimally conscious state [MCS] and unresponsive wakefulness
syndrome [UWS])
5. Which “sedation” scales are valid and reliable in brain-injured patients who require neurocritical
care?
6. What other sedation strategies may lead to improved outcomes for brain-injured patients?
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7. Which delirium scales are valid and reliable in brain-injured patients who require neurocritical care?
Summary 
All clinical scales of consciousness should account for the effects of sedation and neuromuscular 
blockade. Inter-rater reliability assessments of the GCS report a range of kappa scores, but the GCS is a 
strong prognostic marker and indicator of need for surgery in TBI (11); of clinical outcome in posterior 
circulation stroke (12); and following cardiac arrest. (13) In isolation, the GCS is disadvantaged by the 
confounders produced by endotracheal intubation, and by the lack of measurement of pupillary 
responses (which are strong predictors of outcome). However, the prognostic information provided by 
pupillary responses can be integrated with the GCS to provide greater specificity of outcome prediction 
(14). Newer devices provide objective measurement of pupillary diameter, and the amount and speed of 
pupillary response, but additional research is necessary to confirm the role of these devices in caring for 
brain-injured patients.  
Sedation, potent analgesics (e.g. opioids) and neuromuscular blockade remain a problem for any clinical 
scale of consciousness. However, in the non-sedated (or lightly sedated but responsive) patient, the 
recently devised FOUR score, which measures ocular (as well as limb) responses to command and pain, 
along with pupillary responses and respiratory pattern (15), may provide a more complete assessment 
of brainstem function. Volume assist ventilator modes may confound differentiation between the two 
lowest scores of the respiratory component of the FOUR score. The FOUR score has been shown to have 
good inter-rater reliability (16) and prognostic content in a range of neurological conditions, and may 
show particularly good discrimination in the most unresponsive patients. However, experience with this 
instrument is still limited when compared to the GCS. Current evidence suggests that both the GCS and 
FOUR score provide useful and reproducible measures of neurological state, and can be routinely used 
in to chart trends in clinical progress. 
Brain injured patients in neurocritical care units are known to experience more significant pain than 
initially presumed (17). While any level of neurological deficit can confound assessment of pain and 
agitation, perhaps a greater barrier arises from perceptions of clinicians who feel that such assessments 
are simply not possible in such patient populations. In actual fact, up to 70% of neurocritical care 
patients can assess their own pain using a self-reporting tool such as the Numeric Rating Scale (NRS), 
while clinician rated pain using the Behavioral Pain Scale (BPS) is assessable in the remainder. Assessing 
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pain in patients with severe disorders of consciousness such as vegetative state (VS) and minimally 
conscious state (MCS) is a greater challenge, but is possible with Nociception Coma Scale-revised (NCS-
R). (18). 
The assessment of sedation in the context of brain injury is challenging, since both agitation and 
apparent sedation may be the consequence of the underlying neurological state, rather than simply a 
marker of suboptimal sedation. However, both the Richmond Agitation Sedation Scale (RASS) and the 
Sedation-Agitation Scale (SAS) (19) provide workable solutions in some patients.  
“Wake-up tests” in patients with unstable intracranial hypertension pose significant risks often lead to 
physiological decompensation (20), and show no proven benefits in terms of in duration of mechanical 
ventilation, length of intensive care unit and hospital stay, or mortality. However we recognize that in 
some patients (e.g. those with aneurysmal subarachnoid hemorrhage requiring neurological 
assessment) a balance will need to be struck between the information gained from clinical evaluation 
and risk of physiological decompensation with wake-up test. In such circumstances, the benefit of a full 
neurological assessment may be worth a short period of modest ICP elevation. The Confusion 
Assessment Method for the ICU (CAM-ICU) or the Intensive Care Delirium Screening Checklist (ICDSC) 
were strongly recommended for delirium assessment by the 2013 PAD Guidelines (19). While delirium 
assessment has been reported in stroke (21), generalizability of this data is limited, and even within this 
study, as the majority of patients were unassessable. The ICDSC may be preferred since it does not score 
changes in wakefulness and attention directly attributable to recent sedative medication as positive 
ICDSC points. It is important to emphasize that a diagnosis of delirium in a neurocritical care patient may 
represent evidence of progress of the underlying disease, and must prompt an evaluation for a new 
neurologic deficit or specific neurologic process. 
Recommendations 
1. We recommend that assessments with either the GCS (combined with assessment of pupils) or the
FOUR score be routinely performed in comatose adult patients with acute brain injury. (Strong
recommendation, Low quality of evidence).
2. We recommend using the Numeric Rating Scale 0-10 to elicit patient’s self-report of pain in all
neurocritical care patients wakeful enough to attempt this. (Strong recommendation, Low quality of
evidence).
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3. We recommend in the absence of a reliable NRS patient self-report, clinicians use a behavior-based
scale to estimate patient pain such as the BPS or CCPOT. (Strong recommendation, Low quality of
evidence).
4. We recommend use of the revised Nociceptive Coma Scale (NCS-R) to estimate pain for patients
with severely impaired consciousness such as VS or MCS, using a threshold score of 4. (Strong
recommendation, Low quality of evidence).
5. We recommend monitoring sedation with a validated and reliable scale such as the SAS or RASS.
(Strong recommendation, Low quality of evidence).
6. We recommend against performing sedation interruption or wake-up tests among brain-injured
patients with intracranial hypertension, unless benefit outweighs the risk (Strong recommendation,
Low quality of evidence).
7. We suggest assessment of delirium among neurocritical care patients include a search for new
neurologic insults as well as using standard delirium assessment tools. (Weak recommendation,
Low quality of evidence).
8. We recommend attention to level of wakefulness, as used in the ISDSC, during delirium screening
to avoid confounding due to residual sedative effect. (Strong recommendation, Low quality of
evidence).
Systemic Hemodynamics 
Questions Addressed 
1. What hemodynamic monitoring is indicated in patients with acute brain injury?
2. What hemodynamic monitoring is indicated to diagnose and support the management of
unstable or at risk patients?
Summary 
Cardiopulmonary complications are common after acute brain injury (ABI), and have a significant impact 
on clinical care and patient outcome (22-26). Among several hypotheses, the main mechanism of cardiac 
injury following ABI (e.g. subarachnoid hemorrhage [SAH]), is related to sympathetic stimulation and 
catecholamine release (27-29). All patients with ABI admitted to the ICU require basic hemodynamic 
monitoring of blood pressure, heart rate and pulse oximetry. Some stable patients will require nothing 
more than this, but many will need more invasive and/or sophisticated hemodynamic monitoring. 
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Monitoring of systemic hemodynamics contributes to understanding the mechanisms of circulatory 
failure, and detecting or quantifying inadequate perfusion or organ dysfunction. Although there is 
limited evidence, cardiac output should be monitored (invasively or non-invasively) in those patients 
with myocardial dysfunction or hemodynamic instability (30). Whether this also applies to patients on 
vasopressors to augment cerebral perfusion pressure (CPP) rather than for hemodynamic instability 
should be decided on a case-by-case basis. The various hemodynamic devices available have differing 
technical reliability, clinical utility and caveats, but limited studies are available in acute brain injured 
patients. Baseline assessment of cardiac function with echocardiography may be a useful approach 
when there are signs of cardiac dysfunction. Methods for evaluation fluid responsiveness are similar to 
the ones used in the general ICU population. 
Recommendations 
1. We recommend the use of electrocardiography and invasive monitoring of arterial blood
pressure in all unstable or at-risk patients in the intensive care unit (Strong
Recommendation, High quality of evidence).
2. We recommend that hemodynamic monitoring be used to establish goals that take into
account cerebral blood flow and oxygenation. These goals vary depending on diagnosis and
disease stage. (Strong recommendation, High quality of evidence).
3. We recommend the use of additional hemodynamic monitoring (e.g. intravascular volume
assessment, echocardiography, cardiac output monitors) in selected patients with
hemodynamic instability (Strong Recommendation, Moderate quality of evidence).
4. We suggest that the choice of technique for assessing pre-load, after-load, cardiac output,
and global systemic perfusion should be guided by specific evidence and local expertise
(Weak recommendation, Moderate quality of evidence).
Intracranial Pressure and Cerebral Perfusion Pressure 
Questions Addressed 
1. What are the indications for monitoring ICP and CPP?
2. What are the principal methods of reliable, safe and accurate ICP and CPP monitoring?
3. What is the utility of ICP and CPP monitoring for prognosis in the comatose traumatic brain
injury (TBI) patient?
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Summary: 
Monitoring of intracranial pressure (ICP) and cerebral perfusion pressure (CPP) is considered to be 
fundamental to the care of patients with acute brain injury particularly those in coma, and is routinely 
used to direct medical and surgical therapy [31]. ICP and CPP monitoring are most frequently studied 
described in TBI, but can play a similar role in conditions such as SAH and ICH among other disorders. 
Increased ICP and particularly that refractory to treatment, is a well-described negative prognostic 
factor, specifically for mortality [32-34]. There are well-established indications and procedural methods 
for ICP monitoring, and its safety profile is excellent [35]. The threshold that defines intracranial 
hypertension is uncertain but generally is considered to be > 20-25 mm Hg, although both lower and 
higher thresholds are described [36]. The recommendations for an optimal CPP have changed over time 
and may in part be associated with the variability in how mean arterial pressure (MAP) is measured to 
determine CPP (37) and depend on disease state. In addition, management strategies based on 
population targets for CPP rather than ICP have not enhanced outcome (38), and rather than a single 
threshold optimal CPP, values may need to be identified for each individual (39). There are several 
devices available to measure ICP; intraparenchymal monitors or ventricular catheters are the most 
reliable and accurate, but for patients with hydrocephalus a ventricular catheter is preferred. The 
duration of ICP monitoring varies according to the clinical context.  
Recently, our core beliefs in ICP have been challenged by the BEST-TRIP trial [40]. While this study has 
high internal validity, it lacks external validity and so the results cannot be generalized. Furthermore, the 
trial evaluated two treatment strategies for severe TBI, one triggered by an ICP monitor and the other by 
the clinical examination and imaging rather than the treatment of intracranial hypertension. In this 
context it must be emphasized that clinical evaluation and diagnosis of elevated ICP was fundamental to 
all patients in BEST-TRIP, and hence the study reinforces that evaluation and monitoring, either by a 
specific monitor or by an amalgamation of clinical and imaging signs is standard of care.  
ICP treatment is important and is best guided by combination of ICP monitoring, clinical imaging and 
clinical evaluation used in combination and in the context of a structured protocol [41-43]. We recognize 
this may vary across different diagnoses, and different countries. Today, a variety of other intracranial 
monitoring devices are available, and ICP monitoring is a mandatory prerequisite when other 
intracranial monitors are used, to provide a framework for optimal interpretation.  
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Recommendations 
1. ICP and CPP monitoring are recommended as a part of protocol-driven care in patients who are
at risk of elevated intracranial pressure based on clinical and/or imaging features. (Strong
recommendation, Moderate quality of evidence).
2. We recommend that ICP and CPP monitoring be used to guide medical and surgical
interventions and to detect life-threatening imminent herniation; however, the threshold value
of ICP is uncertain based on the literature (Strong recommendation, High quality of evidence).
3. We recommend that the indications and method for ICP monitoring should be tailored to the
specific diagnosis (e.g. SAH, TBI, encephalitis) (Strong recommendation, Low quality of
evidence).
4. While other intracranial monitors can provide useful information, we recommend that ICP
monitoring be used as a prerequisite to allow interpretation of data provided by these other
devices (Strong recommendation, Moderate quality of evidence).
5. We recommend the use of standard insertion and maintenance protocols to ensure safety and
reliability of the ICP monitoring procedure (Strong recommendation, High quality of evidence).
6. Both parenchymal ICP monitors and external ventricular catheters (EVD) provide reliable and
accurate data and are the recommended devices to measure ICP. In the presence of
hydrocephalus, use of an EVD when safe and practical is preferred to parenchymal monitoring
(Strong recommendation, High quality of evidence).
7. We recommend the continuous assessment and monitoring of ICP and CPP including waveform
quality using a structured protocol to ensure accuracy and reliability. Instantaneous ICP values
should be interpreted in the context of monitoring trends, CPP and clinical evaluation. (Strong
recommendation, High quality of evidence).
8. While refractory ICP elevation is a strong predictor of mortality, ICP per se does not provide a
useful prognostic marker of functional outcome; therefore, we recommend that ICP not be used
in isolation as a prognostic marker. (Strong recommendation, High quality of evidence)
Cerebral Autoregulation 
Questions addressed 
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1. Does monitoring of cerebral autoregulation help guide management and contribute to
prognostication?
2. Which technique and methodology most reliably evaluates the state of autoregulation in acute
brain injury?
Summary 
Pressure autoregulation is an important hemodynamic mechanism that protects the brain against 
inappropriate fluctuations in cerebral blood flow (CBF) in the face of changing cerebral perfusion 
pressure (CPP). Both static and dynamic autoregulation have been monitored in neurocritical care to aid 
prognostication and contribute to individualizing optimal CPP targets in patients. (44) Failure of 
autoregulation is associated with a worse outcome in various acute neurological diseases. (45) For 
monitoring, several studies have used ICP (as a surrogate of vascular caliber and reactivity), transcranial 
Doppler ultrasound, and near infrared spectroscopy to continuously monitor the impact of spontaneous 
fluctuations in CPP on cerebrovascular physiology, and calculated derived variables of autoregulatory 
efficiency. However, the inconsistent approaches to using such devices to monitor autoregulation make 
comparison difficult, and there are no good comparative studies that permit us to conclusively 
recommend one approach in preference to another.  
In broad terms, the preservation or absence of pressure autoregulation can influence blood pressure 
management following brain injury. Patients who show preserved autoregulation may benefit from 
higher mean arterial and CPP as part of an integrated management scheme for ICP control, while those 
who show pressure passive responses may be better served by judicious blood pressure control. Critical 
autoregulatory thresholds for survival and favorable neurological outcome may be different, and may 
vary with age and sex. The brain may be particularly vulnerable to autoregulatory dysfunction during 
rewarming after hypothermia and within the first days following injury. (46) 
More refined monitoring of autoregulatory efficiency is now possible through on-line calculation of 
derived indices such as the pressure reactivity index (PRx). (45) About two-thirds of TBI patients have an 
optimum CPP range (CPPopt) where their autoregulatory efficiency is maximized, and that management 
at or close to CPPopt is associated with better outcomes. (47) The safety of titrating therapy to target 
CPPopt requires further study, and validation in a formal clinical trial before it can be recommended. 
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Recommendations 
1. We suggest that monitoring and assessment of autoregulation may be useful in broad targeting of
cerebral perfusion management goals and prognostication in acute brain injury. (Weak
recommendation, Moderate quality of evidence).
2. Continuous bedside monitoring of autoregulation is now feasible, and we suggest that should be
considered as a part of multimodality monitoring.  Measurement of pressure reactivity has been
commonly used for this purpose, but many different approaches may be equally valid. (Weak
recommendation, Moderate quality of evidence)
Systemic and Brain Oxygenation 
Questions addressed 
1. What are the indications for brain and systemic oxygenation in neurocritical care patients?
2. What are the principal methods of reliable and accurate brain oxygen monitoring?
3. What is the safety profile of brain oxygen monitoring?
4. What is the utility of brain oxygen monitoring to determine prognosis in the comatose patient?
5. What is the utility of brain oxygen monitoring to direct medical and surgical therapy?
6. What is the utility of brain oxygen monitoring to improve neurological outcome?
Summary 
Maintenance of adequate oxygenation is a critical objective of managing critically ill patients with 
neurological disorders. Assessing tissue oxygenation provides vital information about oxygen supply and 
consumption in tissue beds. Inadequate systemic and brain oxygen aggravates secondary brain injury. 
Multimodality brain monitoring includes measuring oxygenation systemically and locally in the brain. 
Systemic oxygenation and carbon dioxide (CO2) can be measured invasively with blood gas sampling and 
non-invasively with pulse oximetry and end tidal CO2 devices. There is extensive research in the general 
critical care population on safety and applicability of systemic oxygen and carbon dioxide monitoring. 
PaO2, SaO2, and SpO2 are indicators of systemic oxygenation and useful to detect oxygenation decreases. 
Periodic measurements of PaO2 and SaO2 and continuous SpO2 measurements should be used to guide 
airway and ventilator management in patients who require neurocritical care (48,49). PaCO2 is a reliable 
measurement of hyper- or hypo-capnia and is superior to ETCO2 monitoring. The continuous monitoring 
of ETCO2 and periodic monitoring of PaCO2 assists in ventilator management. (50) The optimal target 
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values for PaO2, SaO2 and SpO2 specific to the NCCU patient population are still being elucidated. 
Normoxemia and avoidance of hypoxemia and hyperoxemia should be targeted.  
Brain oxygen measurements include two invasive bedside techniques, brain parenchymal oxygen 
tension (PbtO2) and jugular bulb oxygen saturation (SjvO2), or a non-invasive bedside method, near 
infrared spectroscopy (NIRS). Normal PbtO2 is 23-35 mmHg. (51) A PbtO2 threshold <20 mmHg 
represents compromised brain oxygen and is a threshold at which to consider intervention. Decreases 
below this are associated with other markers of cerebral ischemia or cellular dysfunction although exact 
values vary slightly with the type of parenchymal monitor used and should be interpreted based on 
probe location identified on a post-insertion CT. (52, 53) However, PbtO2 is not simply a marker of 
ischemia or CBF. PbtO2 monitoring is safe and provides accurate data for up to 10 days with measured 
responses to interventions (e.g. changes in CPP, ventilator targets, pharmacologic sedation, and 
transfusion) and can be used to guide therapy. (54) Observational studies suggest a potential benefit 
when PbtO2-guided therapy is added to a severe TBI management protocol, but there remains clinical 
equipoise.  
SjvO2 values differ from PbtO2 in what is measured and can be used to detect both ischemia and 
hyperemia. Positioning, clot formation on the catheter, and poor sampling technique can influence SjvO2 
accuracy and errors are common so making SjvO2 monitoring more difficult to use and less reliable than 
PbtO2 monitoring. (55) Normal SjvO2 is between 55-75%. Cerebral ischemia is present when SjvO2 < 55%, 
(56), but cannot reliably be assumed to be absent at higher values since regional abnormalities may not 
be detected (57). The majority of SjvO2 studies are in severe TBI patients with limited studies in SAH, ICH 
or ischemic stroke patients. SjvO2 values can guide therapy (58) but have not been shown to improve 
outcomes. NIRS has several limitations in adult use (59). There are limited small observational studies 
with conflicting results about desaturations related to cerebral perfusion, vasospasm, head positioning 
during impending herniation, pharmacologic interventions, and changes in MAP/CPP. There are no 
studies that demonstrate that data from NIRS use alone can influence outcomes in adult neurocritical 
care.  
Recommendations 
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1. We recommend systemic pulse oximetry in all patients and end-tidal capnography in
mechanically ventilated patients, supported by arterial blood gases measurement (Strong
Recommendation, High quality of evidence).
2. We recommend monitoring brain oxygen in patients with or at risk of cerebral ischemia
and/or hypoxia, using brain tissue (PbtO2) or/and jugular venous bulb oximetry (SjvO2); the
choice of which depends on patient pathology (Strong recommendation, Low quality of
evidence).
3. We recommend that the location of the PbtO2 probe and side of jugular venous oximetry
depend on the diagnosis, the type and location of brain lesions and technical feasibility.
(Strong recommendation, Low quality of evidence).
4. While persistently low PbtO2 and/or repeated episodes of jugular venous desaturation are
strong predictors of mortality and unfavorable outcome, we recommend that brain oxygen
monitors be used with clinical indicators and other monitoring modalities for accurate
prognostication. (Strong recommendation, Low quality of evidence)
5. We suggest the use of brain oxygen monitoring to assist titration of medical and surgical
therapies to guide ICP/CPP therapy, identify refractory intracranial hypertension and
treatment thresholds, help manage delayed cerebral ischemia, and select patients for
second tier therapy. (Weak recommendation, Low quality of evidence).
Cerebral Blood Flow 
Questions addressed 
1. What are the indications for cerebral blood flow (CBF) monitoring?
2. Do the various CBF monitors reliably identify those patients at risk for secondary ischemic
injury?
3. What CBF neuromonitoring thresholds best identify risk for ischemic injury?
4. Does use of CBF neuromonitoring improve outcomes for those patients at risk for ischemic
injury?
Summary 
Measurement of cerebral blood flow (CBF) has long been used in experimental models to define 
thresholds for ischemia leading to interest in monitoring CBF in patients, in large part because ischemia 
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can underlie secondary cerebral injury. In addition to radiographic methods (not covered here) several 
devices can be used at the patient’s bedside to monitor for CBF changes. These radiographic studies, 
particularly PET have demonstrated that cellular injury often can occur in the absence of ischemia 
(60,61). Advances in our understanding of the pathophysiology of TBI and ICH suggest, however, that 
traditional ischemic thresholds may not always apply and CBF data should be coupled with 
measurements of metabolic demand.  
Flow can be continually monitored in a single small region of brain using invasive thermal diffusion 
flowmetry (TDF) or less commonly, laser Doppler flowmetry (LDF) (62, 63). The utility of these probes is 
limited by their invasive nature, small field of view, and uncertainly as to where they should be placed. 
TDF use is limited by reduced reliability in patients with elevated systemic temperatures. There are few 
data regarding ischemic thresholds for these devices.  
Blood flow in larger regions of brain can be estimated by transcranial Doppler ultrasonography (TCD), 
although accuracy may be limited by operator variability. TCD is primarily used to monitor for 
vasospasm following aneurysmal subarachnoid hemorrhage (SAH). TCD also can be used to identify TBI 
patients with hypoperfusion or hyperperfusion and so guide their care. However there is a far greater 
body of literature describing TCD use in SAH. TCD can predict angiographic vasospasm with good 
sensitivity and specificity (64,65) but is less accurate in predicting delayed ischemic neurological deficits 
(66). Predictive power is improved with the use of transcranial color-coded duplex sonography (TCCS) 
(67). Inclusion of the Lindegaard ratio (68) and the rate of the increase in velocities (69) in interpreting 
the data improves performance. There are no published studies that demonstrate enhanced outcomes 
that result from implementation of a treatment strategy directed only by neuromonitoring devices that 
assess CBF or ischemic risks.  
Recommendations 
1. We recommend TCD or TCCS monitoring to predict angiographic vasospasm after aneurysmal
subarachnoid hemorrhage (Strong recommendation, High quality of evidence).
2. We suggest that trends of TCD or TCCS can help predict delayed ischemic neurological deficits
due to vasospasm after aneurysmal subarachnoid hemorrhage (Weak recommendation,
Moderate quality of evidence).
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3. We suggest that TCCS is superior to TCD in the detection of angiographically proven vasospasm
after aneurysmal subarachnoid hemorrhage (Weak recommendation, Low quality of evidence).
4. We suggest TCD or TCCS monitoring can help predict vasospasm after traumatic subarachnoid
hemorrhage (Weak recommendation, Very low quality of evidence).
5. We suggest that a TDF probe may be used to identify patients with focal ischemic risk within the
vascular territory of the probe (Weak recommendation, Very low quality of evidence).
6. We suggest use of a TCD screening paradigm using Lindegaard ratios or comparisons of bi-
hemispheric middle cerebral artery mean velocities to improve sensitivity for identification of
vasospasm associated ischemic damage (Weak recommendation, Low quality of evidence).
7. We suggest that TDF probes used to assess ischemic risk after aneurysmal SAH should be placed
in the vascular territory of the ruptured aneurysm (Weak recommendation, Very low quality of
evidence).
Electrophysiology 
Questions Addressed 
1. What are the indications for electroencephalography (EEG)?
2. What is the utility of EEG following convulsive status epilepticus (cSE) and refractory status
epilepticus?
3. What is the utility of EEG or evoked potentials (EPs) in patients with and without acute brain
injury, including cardiac arrest, and unexplained alteration of consciousness?
4. What is the utility of EEG to detect ischemia in patients with subarachnoid hemorrhage or acute
ischemic stroke (AIS)?
5. Should scalp and/or intracranial EEG be added to patient undergoing invasive brain monitoring?
Summary 
Electroencephalography (EEG) and evoked potentials (EPs) are the most frequently used 
electrophysiological techniques used in the ICU (70). EEG provides information about brain electrical 
activity and it is essential to detect seizures, including duration and response to therapy and can help 
outcome prediction after coma. (71-74) Seizures are frequent with and without acute brain injury in the 
ICU, and are mostly nonconvulsive. Further, some patients will have cyclic seizure patterns, which will 
only be detectable by continuously (cEEG) recorded data. (75) However, data to support the benefit of 
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continuous over routine EEG recordings, typically no longer than 30-minute duration (sometimes called 
“spot EEG”) to detect seizures is very limited. Routine EEG will miss nonconvulsive seizures (NCSz) in 
approximately half of those with seizures when compared to prolonged monitoring. (76) Advances in 
neuroimaging have limited the application of EPs in many ICUs, but in select patients EPs can help in 
outcome prediction. 
The optimal montage and number of electrodes to record EEG in the ICU is uncertain and the practicality 
of placing many electrodes in an electrophysiologically unfriendly environment needs to be considered. 
Quantitative EEG algorithms have been developed to support the time-consuming expert review of cEEG 
recordings in the ICU setting. Several studies have highlighted concern regarding the use of bispectral 
index score (BIS) measurements as an EEG quantification tool, stressing large intra-individual and inter-
individual variability, as well as interferences. Data do not support BIS for brain-injured patients in the 
ICU. 
Recommendations 
1. We recommend EEG in all patients with acute brain injury and unexplained and persistent
altered consciousness (Strong recommendation, Low quality of evidence).
2. We recommend urgent EEG in patients with cSE that do not return to functional baseline within
60 min after seizure medication and we recommend urgent (within 60 min) EEG in patients with
refractory SE (Strong recommendation, Low quality of evidence).
3. We recommend EEG during therapeutic hypothermia and within 24 h of rewarming to exclude
NCSz in all comatose patients after cardiac arrest (CA) (Strong recommendation, Low quality of
evidence).
4. We suggest EEG in comatose ICU patients without an acute primary brain condition and with
unexplained impairment of mental status or unexplained neurological deficits to exclude NCSz,
particularly in those with severe sepsis or renal/hepatic failure (Weak recommendation, Low
quality of evidence).
5. We suggest EEG to detect delayed cerebral ischemia (DCI) in comatose SAH patients, in whom
neurological examination is unreliable (Weak recommendation, Low quality of evidence).
6. We suggest continuous EEG monitoring as the preferred method over routine EEG monitoring
whenever feasible in comatose ICU patients without an acute primary brain condition and with
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unexplained impairment of mental status or unexplained neurological deficits to exclude NCSz 
(Weak recommendation, Low quality of evidence). 
Cerebral Metabolism 
Questions addressed 
Summary 
Brain metabolism in humans can be monitored at bedside using cerebral microdialysis. Brain 
extracellular concentrations of energy metabolism markers, including lactate, pyruvate and glucose, are 
accurately measured by microdialysis. Their variations over time, and in response to therapy, can help 
clinical management (77,78) and are not markers of ischemia alone but also reflect energy metabolism 
in the brain. (79,80) In TBI, cerebral microdialysis may contribute to prognostication and abnormalities 
appear to be associated with long-term tissue damage. (81,82) In SAH microdialysis may provide insight 
on inadequate energy substrate delivery (83) and on markers of delayed cerebral ischemia. (84) 
Cerebral microdialysis has an excellent safety record. However, there are limitations in that it is a focal 
measurement, disclosing different metabolite concentrations when inserted in pathological or 
preserved brain areas and so microdialysis should be interpreted based on location defined by post-
insertion CT. (85) The technique can be labor intensive for bedside point of care monitoring and 
interpretation. Metabolite collection also occurs over time (e.g. 60 minutes) and so data is delayed 
rather than real-time. Microdialysis when used with other monitors can enhance understanding of brain 
physiology and also when used for research may provide novel insights into pathophysiological 
mechanisms and on various treatment modalities that directly affect brain metabolism and function. 
Recommendations 
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1. We recommend monitoring cerebral microdialysis in patients with or at risk of cerebral
ischemia, hypoxia, energy failure, and glucose deprivation (Strong recommendation, Low quality
of evidence).
2. We recommend that the location of the microdialysis probe depend on the diagnosis, the type
and location of brain lesions and technical feasibility. (Strong recommendation, Low quality of
evidence).
3. While persistently low brain glucose and/or an elevated lactate/pyruvate ratio are strong
predictors of mortality and unfavorable outcome, we recommend that cerebral microdialysis
only be used in combination with clinical indicators and other monitoring modalities for
prognostication. (Strong recommendation, Low quality of evidence).
4. We suggest the use of cerebral microdialysis to assist titration of medical therapies such as
systemic glucose control and the treatment of delayed cerebral ischemia (Weak
recommendation, Moderate quality of evidence).
5. We suggest the use of cerebral microdialysis monitoring to assist titration of medical therapies
such as transfusion, therapeutic hypothermia, hypocapnia and hyperoxia (Weak
recommendation, Low quality of evidence).
Glucose and Nutrition 
Questions addressed 
1. Can measuring energy expenditure with indirect calorimetry be used to monitor the nutritional
requirements in patients who require neurocritical care? 
2. What methods are useful when monitoring the response to nutritional interventions?
3. Is there utility in monitoring gastric residuals in patients receiving enteral nutrition?
4. How should glucose monitoring be performed in the acute critical care period after brain injury?
5. Should monitoring of serial blood glucose values be performed routinely during the critical care after
acute brain injury? 
Summary 
The monitoring of glycemic control and nutritional status are important features of intensive care (86), 
and interface with multimodality monitoring in important ways. Early profound hyperglycemia is 
independently associated with poor prognosis after TBI, stroke and SAH. Several lines of evidence 
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support a need to avoid hypoglycemia, low brain glucose, and extreme hyperglycemia during intensive 
care and reinforce the need for accurate, reliable and frequent glucose measurements. [87] Use of acute 
point of care testing of arterial or venous blood, and the use laboratory-quality measures of glucose are 
critical. [88,89] Understanding glycemic control is central to determining the status of energy substrate 
delivery to the brain and assists in understanding the findings observed using cerebral microdialysis. 
[90,91] At the same time, the assessment of nutritional status and protein balance are important, albeit 
more challenging, to reliably and repeatedly perform in the ICU. Several tenets of clinical care have 
recently been questioned, including the use of indirect calorimetry, energy estimation formulas [92], 
and the monitoring of gastric residuals. (93] Many studies support the concept that acute brain injury 
induces a hypercatabolic state, and hence caloric and protein supplementation is needed. However, 
changing strategies of sedation and therapeutic normothermia may affect the metabolic state and 
hence justify a need to establish measures of nutritional balance. The influence of inadequate protein 
balance may influence glycemic control and hence brain metabolism, but this linkage remains poorly 
studied at this time.  
Recommendations 
1. We suggest against the routine monitoring of nutritional requirements with measurement of energy
expenditure by indirect calorimetry or the use of estimating equations for assessing nutritional 
requirements (Weak recommendation, Low quality of evidence) 
2. We recognize that accurately measuring nitrogen balance is difficult, but where this is possible we
suggest that this may be used to help assess the adequacy of nutritional support (Weak 
recommendation, Very low quality of evidence). 
3. We suggest against the use of anthropometric measurements or serum biomarkers as a method by
which to monitor the overall responsiveness of nutritional support. (Weak recommendation, Very low 
quality of evidence). 
4. We recommend against routine monitoring of gastric residuals in mechanically ventilated patients
(Strong recommendation, High quality of evidence). 
5. We recommend that arterial or venous blood glucose be measured by a laboratory-quality glucose
measurement immediately upon admission, to confirm hypoglycemia, and during low perfusion states 
for patients with acute brain injury (Strong recommendation, High quality of evidence).  
6. We recommend serial blood glucose measurements using point of care testing should be performed
routinely during critical care after acute brain injury. (Strong recommendation, High quality of evidence). 
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Hemostasis and Hemoglobin 
Questions addressed 
1. What are the indications for monitoring hemoglobin?
2. How should hemoglobin monitoring be performed in acute brain injury?
3. When and how frequently should hemoglobin be measured?
4. What hemostatic monitoring parameters should be performed in acute brain injury and in
the perioperative setting?
Summary 
Anemia and bleeding are frequent in patients who suffer severe neurologic insults and are associated 
with worse outcomes. (94) Serial measurements of hemoglobin (Hgb) concentration are necessary to 
assess and monitor for the development of anemia. Non-invasive monitoring of Hgb limits blood loss, 
but has suboptimal accuracy and precision compared to standard laboratory testing. Efforts to minimize 
volume of blood sampled for laboratory assessment are effective in ameliorating anemia. (95) No data 
establish benefit of a particular frequency of Hgb monitoring. Transfusion has been linked to worse 
outcomes (96) although the interaction with anemia makes separating their effects difficult. The 
transfusion threshold used in general critical care may not apply to all patients with acute neurological 
disorders and may vary with pathology, the patient, and their cerebrovascular reserve. 
Point-of-care-testing (POCT) detects the effect of non-steroidal anti-inflammatory drugs on platelet 
activity (97) and can be used to monitor normalization of platelet function after drug withdrawal (98) 
and platelet transfusion (99), but data are limited. In patients taking novel oral anticoagulants, 
information regarding time of last dose ingestion, renal function, and age may accurately determine 
plasma concentrations. (100) Thrombin time, PT and aPTT can be used to help monitor these agents and 
may suggest anticoagulant effect, but may not be accurate at low concentrations. The direct thrombin 
Inhibitor (DTI) assay determines both the anticoagulant activity and plasma concentration of dabigatran 
(101) whereas specific factor Xa assays can detect the presence of rivaroxaban, apixiban or edoxaban.
These assays are beginning to become more widely available in the clinical environment. 
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Pre-operative screening for neurosurgical procedures routinely includes a bleeding history (102) and 
measurement of the PT and aPTT. (103) Yet, whether minimal elevations of the PT or INR correlate with 
increased bleeding risk is uncertain and may depend in part on the procedure. (104) An INR <1.6 and a 
platelet count >100,000 are reasonable goals but depend on patient disease. ICP monitor placement in 
patients with liver failure often leads to hemorrhage (105) and accurate assessment of hemostasis is of 
paramount importance. The INR is traditionally used to guide treatment; however, it is widely 
acknowledged to be inaccurate in this population. (106)  
Recommendations 
1. We recommend that monitoring Hgb should be done in all patients (Strong recommendation,
Moderate quality of evidence).
2. We recommend that central laboratory methods be used for the accurate and reliable
monitoring of hemoglobin and hemostatic values (Strong recommendation, Moderate quality of
evidence).
3. POCT may help identify coagulopathy or antiplatelet agent use in patients with TBI, SAH and ICH
where there is a concern for platelet dysfunction (Strong recommendation, Moderate quality of
evidence).
4. POCT may be used to monitor the response to interventions intended to improve platelet
function. (Weak recommendation, Very low quality of evidence).
5. In patients who require neurosurgical intervention, a detailed family history and structured
screening about bleeding disorders and bleeding after traumatic events, should be elicited.
(Strong recommendation, Moderate quality of evidence).
6. Determination of time of last ingested dose, renal function, age, and other medications ingested
is recommended to assist in determination of plasma concentration of the new anticoagulants.
(Strong recommendation, High quality of evidence).
7. We suggest that, if available, new specific assays for the new oral anticoagulants be used to
assess coagulation status in neurologic emergencies. (Weak recommendation, Low quality of
evidence).
8. In patients with liver failure, routine tests of coagulation may not accurately reflect hemostatic
balance. Advanced tests of coagulation, point-of-care devices, and consultation with a
hematologist are suggested. (Weak recommendation, Low quality of evidence).
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Temperature and Inflammation 
Questions addressed 
1. Does continuous monitoring of temperature improve our discrimination of bad outcomes more than
episodic monitoring?
2. Does monitoring of temperature improve our ability to discriminate infection vs. brain-derived
fever?
3. Is brain temperature or core body temperature optimal to determine temperature in critically ill
neurologic patients?
4. How should shivering be monitored in patients receiving therapeutic temperature modulation?
5. What inflammatory cells predict outcome in acute brain disease?
6. Is there utility in monitoring inflammatory mediators?
Summary 
In patients with acute brain injury, the incidence of fever is greater than in general ICU patients and is a 
marker for poor outcome. Patients who have active treatment of fever have less evidence of metabolic 
crisis diagnosed by cerebral microdialysis (107) and induced normothermia can help control intracranial 
pressure. (108) The temperature cut off for fever is unclear, but the common definition of fever is a 
systemic temperature elevation greater than 38.2C or 38.5C There is little evidence that temperature 
monitoring can discriminate between central fever and other causes although some studies suggest that 
the area under the curve of a fever curve is higher in patients with a presumed central fever. (109,110)  
Temperature can be monitored from a number of different sites. Rectal and bladder temperatures are 
more closely associated with pulmonary artery catheter temperatures, whereas oral temperatures are 
superior to axillary and tympanic measurements. (111,112) In brain injured patients central and brain 
temperature show good correlation and so core temperature is a reasonable surrogate for brain 
temperature. Knowledge about temperature (brain or core) can be important in assessing accuracy of 
other monitors including from some types of brain oxygen and CBF devices. Shivering results in 
increases in resting energy expenditure and in the systemic rate of oxygen consumption (VO2) (113) and 
can adversely affect brain metabolism. (114) Hourly measurements using the Bedside Shivering 
Assessment Scale (BSAS) is a reliable method by which to adjust anti-shivering therapy. (115) 
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In SAH, comparison of neutrophil percentage in ventricular fluid in the first three days to other 
predictive scales suggests that it has good negative predictive value for patients who may develop 
delayed deterioration. (116) There is no evidence to support the use of WBC counts or indices of WBC to 
discriminate between infection and inflammatory changes in patients with EVDs. There are a variety of 
inflammatory markers that can be monitored: CRP and Pro-calcitonin are most frequently measured. 
While CRP may provide indirect confirmation of an infection or response to therapy, it does not reliably 
discriminate between bacterial meningitis from other forms of inflammation and has poor predictive 
value in SAH, ICH or stroke. Procalcitonin does not appear to be a useful monitoring technique to 
investigate infections in brain-injured patients. (117) 
Recommendations 
1. In patients with acute neurological injury, we recommend continuous monitoring of temperature
when feasible and, at least hourly if not feasible (Strong recommendation, Low quality of evidence).
2. We recommend that temperature monitoring alone cannot be used as a tool to discriminate
infectious fever from central or neurogenic fever (Strong recommendation, Low quality of evidence).
3. We recommend monitoring core body temperature as a surrogate of brain temperature unless brain
temperature is available from devices placed for other reasons (Strong recommendation, Low quality
of evidence).
4. We recommend hourly monitoring for shivering with the BSAS during therapeutic temperature
modulation. (Strong recommendation, Moderate quality of evidence).
5. We suggest suggest daily measurement of blood leukocyte counts in patients with SAH who are at risk
for delayed deterioration. (Weak recommendation, Low quality of evidence).
6. We suggest against monitoring routine ventricular fluid WBC counts to discriminate whether patients
with EVDs have infection. (Weak recommendation, Low quality of evidence).
7. We suggest against monitoring inflammatory mediators routinely. (Weak recommendation, Low
quality of evidence).
8. We suggest monitoring brain temperature when such a device is placed for other reasons. (Weak
recommendation, Low quality of evidence).
Cellular Damage and Degeneration 
Questions Addressed 
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1. Are there cellular/molecular biomarkers that help predict long-term neurological prognosis in
comatose cardiac arrest patients, either treated or not treated with therapeutic hypothermia (TH)?
2. Are there cellular/molecular biomarkers that help predict a) long term outcome and b)
development of vasospasm and/or DCI after SAH?
3. Are there cellular/molecular biomarkers that help predict a) long term outcome and b) incidence of
malignant cerebral ischemia or hemorrhagic transformation following AIS?
4. Are there cellular/molecular biomarkers that help predict a) long term outcome and b) hematoma
expansion and cerebral edema following intracerebral hemorrhage (ICH)?
5. Are there cellular/molecular biomarkers that help predict a) long term outcome and b) cerebral
edema and ICP elevation after TBI?
Summary 
Numerous candidate molecular biomarkers have been identified and are potentially associated with 
outcome and disease-specific secondary complications of acute brain injury. Most biomarkers have real-
world challenges related to lack of availability, lack of agreement about sample collection and 
processing protocols, wide ranges of threshold values, poor definition of biomarker time course, and 
biological, treatment and laboratory standardization.  
Neuron specific enolase (NSE) is probably the most widely studied currently available biomarker in the 
context of cardiac arrest. Early studies suggested that an elevated NSE at 24-72 hours post-cardiac arrest 
had 100% specificity for poor outcomes in patients not treated with TH. (73) This finding has been 
broadly confirmed in other reports, although the cutoff values vary between studies. However, this 
relationship no longer holds in patients who are treated with TH, and elevated NSE at 24-48 hours post 
cardiac arrest can be seen in these patients who survive with good outcome (74). While S100B and 
combinations of biomarkers have also been evaluated in cardiac arrest treated with TH, and sometimes 
found to perform better than NSE, none of the data provide robust enough outcome prediction to justify 
routine clinical use in this setting (118).  
No biomarkers have been validated in large cohort studies in acute ischemic stroke, SAH, or ICH. While 
individual small studies have explored several biomarkers, none has provided data of adequate quality 
to allow clinical prognostication and decision support. Several biomarkers have been studied in larger 
cohorts of patients with TBI, but sample sizes are still relatively small in the context of this highly 
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heterogeneous disease. (119,120) Although one meta-analysis supports the use of S100B as a biomarker 
of severity and outcome in TBI (121), clinical implementation of this monitoring strategy is limited, in 
part because S100B is not brain specific.  
A number of experimental biomarkers (e.g. glial fibrillary acid protein [GFAP], matrix metalloprotease-9 
[MMP-9], ubiquitin c-terminal hydrolase L1 [UCH-L1] and alpha-II spectrin breakdown products [SBDP]) 
have been suggested to hold promise in acute neurological disease, but have not undergone substantive 
evaluation and are not in routine clinical use. (119,122,123) Although some data suggest that the 
combination of multiple biomarkers or biomarkers and other monitoring modalities can improve 
precision (118-120, 124, 125), large prospective studies are necessary to determine which of these 
biomarkers can be used clinically, to help direct therapy and predict outcome.  
Recommendations 
1. In comatose post-cardiac hypoxic-ischemic encephalopathy (HIE) patients not treated with TH, we
suggest the use of serum NSE in conjunction with clinical data for neurologic prognostication (Weak
recommendation, Moderate quality of evidence).
2. We recommend against the use of serum NSE for prognostication in HIE treated with TH (Strong
Recommendation, Moderate quality of evidence).
3. We recommend against the routine use of molecular biomarker for outcome prognostication in AIS,
SAH, ICH, or TBI (Strong Recommendation, Low quality of evidence).
ICU Processes of Care and Quality Assurance 
Questions 
1. In critically ill patients with acute brain injury, how does care by a dedicated neurointensive care
unit/team impact outcomes?
2. In the neurocritical care population, how does use of evidence based protocols impact patient
outcomes?
3. What are key quality indicators for ICU processes of care and are these applicable to the
neurocritical care population?
Summary 
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Patients with neurological conditions account for 10-15% of all intensive care unit (ICU) admissions. In 
patients with critical neurologic illness patient care in specialized neurocritical care units or by physicians 
and nursing staff with expertise in neurocritical care within a general critical care unit appear to have a 
positive impact on mortality, length of stay, and in some cases, functional outcome. (126-131) By 
contrast delays in care may adversely affect outcome. (132,133) The results, however, are 
heterogeneous and whether the relationship is causal is still being elucidated. In these studies various 
practice modifications, such as implementation of disease or treatment specific protocols or bundles of 
care, staffing requirements, and clustering of neurocritical care patients within a multidisciplinary unit, 
are also temporally associated with outcome improvements.  
Implementation of and adherence to evidence-based protocol-directed care in the neurocritical care 
population has also been shown to be important. (134) Significant evidence exists supporting quality 
indicators that include measures of process (appropriate delivery of health care), outcome (measured 
endpoints of care) and structure (adequate resources to provide health care), for the general ICU 
population (135), but there is limited research about their specific use in neurocritical care. Although 
quality indices for neurocritical care have been proposed, additional research is needed to further 
validate these measures since there appear to be differences between neurocritical care and general 
critical care patients in large acuity- adjusted benchmark studies. (136) 
Recommendations 
1. We recommend that critically ill patients with acute brain injury be managed either in a
dedicated neurocritical care unit or by clinical teams with expertise in neurocritical care (Strong
recommendation, Moderate quality of evidence).
2. We recommend implementation of and monitoring adherence to evidence-based protocols, in
the neurocritical care population (Strong recommendation; Moderate quality of evidence).
3. We recommend that the incidence of ventriculostomy-related infections may be a useful
indicator of quality of care (Strong recommendation, Moderate quality of evidence).
4. We recommend that use of protocols for moderate glycemic control is a useful indicator of
quality of care in neurocritical care patient populations (Strong recommendation; Moderate
quality of evidence).
5. We suggest that other known ICU processes of care including pressure ulcers, central line-
associated blood stream infections, and catheter-associated-urinary tract infections may be
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useful as indicators of general intensive care but none are specific indicators of quality in the 
neurocritical care population (Weak recommendation, Low quality of evidence).  
6. We suggest that ventilator associated pneumonia should not be regarded as a quality indicator
in the neurocritical care population (Weak recommendation, Low quality of evidence).
Multimodality monitoring: Informatics, Integration, Data Display and Analysis 
Questions addressed 
1. Should ergonomic data displays be adopted to reduce clinician cognitive burden?
2. Should clinical decision support tools be adopted to improve clinical decision-making?
3. Should high-resolution physiologic data be integrated with lower resolution data?
4. Should human-centered design principles and methods be used to develop technology
interventions for the intensive care unit?
5. Should devices use data communication standards to improve data connectivity?
6. Should multiparameter alarms and other methods of ‘smart’ alarms be adopted to comply with
the Joint Commission mandate requiring hospitals to address alarm fatigue?
Summary 
Multimodal monitoring generates an enormous amount of data, including written, ordinal, continuous 
and imaging data in the typical patient with a neurologic disorder in the ICU. The frequency and 
resolution at which physiological data are acquired and displayed may vary depending on the signal, 
technology and purposes. (137,138) Clinicians may be confronted with more than 200 variables when 
evaluating a patient (139), with the risk of “information overload” that can lead to preventable medical 
errors. (140) In addition, data are essentially meaningless unless annotated so that providers can search 
for “epochs of interest”, effects of therapies or identify potential artifacts.  
All relevant patient data, acquired at various resolution rates, have to be integrated, since dynamic 
systems are based on relationships that can only be understood by data integration. However, there are 
several obstacles to this, such as proprietary drivers from commercial vendors and time-synchronization 
among others. Hence, standardization of an informatics infrastructure including data collection, data 
visualization, data analysis, and decision support is essential. (141) The goal of data visualization and a 
clinical informatics program is to provide clinical decision support that enhances clinician situational 
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awareness about the patient state. Ergonomic data displays that present results from analyses with 
clinical information in a sensible uncomplicated manner improves clinical decision-making. (142). This 
field of bio-informatics is rapidly evolving and dynamic and so its role in critical care is still to be fully 
elucidated. 
Recommendations 
1. We recommend utilizing ergonomic data displays that present clinical information in a sensible
uncomplicated manner to reduce cognitive load and improve judgments of clinicians (Strong 
recommendation, Moderate quality of evidence). 
2. We suggest using clinical decision support tools such as algorithms that automatically process
multiple data streams with the results presented on a simple, uncomplicated display (Weak 
recommendation, Moderate quality of evidence). 
3. We recommend adopting a database infrastructure that enables the integration of high-resolution
physiologic data (including EEG recordings) with lower resolution data from laboratory and electronic 
health care systems (Strong recommendation, Low quality of evidence). 
4. We recommend following an iterative, human-centered design methodology for complex visualization
displays to avoid adversely affecting clinical decision-making (Strong recommendation, Moderate quality 
of evidence). 
5. We recommend device manufacturers utilize data communication standards including time
synchronization on all devices to improve usability of its data (Strong recommendation, Low quality of 
evidence). 
6. We recommend adopting “smart” alarms in the intensive care unit to help address alarm fatigue
(Strong recommendation, Low quality of evidence). 
Monitoring in Emerging Economies 
Questions addressed 
1. Are there differences between high-income countries (HICs) and low- and middle -income
countries (LAMICs) in baseline characteristics for neurocritical care patients or selection of
patients for study?
2. What is the availability/penetration of various monitoring technologies/ neurocritical care in
emerging economies?
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3. Does MMM benefit patients in LAMICs and is it cost-effective?
4. What are the challenges to instituting MMM in resource-constrained environments?
Summary 
The burden of disease and so the need for care often is greater at hospitals in emerging economies. For 
example, 90% of trauma-related deaths are estimated to occur in the developing world (143). Emerging 
economies represent a heterogeneous group of countries. Furthermore there may be differences in 
economic scale and available resources in HICs even within cities and health care systems. The selection 
criteria for ICU admission are not clearly defined in most studies and ICU bed availability is an important 
factor in resource-limited settings whereas decisions about futility become important in HICs. Even in 
middle-income environments, some severe TBI patients are ventilated in general wards influenced by 
bed availability and the expected outcome. (144) In addition, in large studies the demographics of the 
studied population in LAMICs often differs from that in HICs (145). 
Advanced monitoring in neurocritical care is uncommon in emerging economies. Some exceptions do 
occur and monitoring ICP, brain oxygen, CBF, continuous EEG, jugular venous saturation, and 
microdialysis, often in combination, have all been described at centers based in emerging economies; 
but are concentrated where there is an interest in neurocritical care and in particular from Latin 
America, Malaysia, South Africa, and China (e.g. 146, 147). ICP monitoring often is considered a 
fundamental tool in neuromonitoring but in emerging economies is not commonly employed outside of 
specialist centers. However, there also is great variability in use of these devices even within HICs. (43) 
In LAMICs ventricular, subdural or subarachnoid catheters often are used instead of the more expensive 
parenchymal devices; this can affect interpretation of comparative studies. A recent randomized, 
controlled trial (RCT) conducted in general ICUs in Bolivia and Ecuador, introduced ICP to an 
environment where they had not been used previously to evaluate two management protocols in severe 
TBI (40) Outcome was similar in the two treatment groups and has raised questions about the value of 
advanced monitoring in this environment. However, the use of ICP monitors was associated with more 
efficient care, which may prove to be important in cost effective care in a resource- limited 
environment. Furthermore, ICP monitoring may help reduce the frequency of potentially inappropriate 
ICP-lowering therapies. There is indirect evidence to support aggressive management for severe TBI in 
LAMICs, including the use of advanced monitoring. Decision analysis suggests that this can be associated 
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with cost effective outcome enhancement (148). There is no evidence that patients in LAMICs should be 
treated differently than patients in HICs.  
It should be recognized there is a wide range in expertise and resources not only within the LAMICs but 
also within individual HICs. Several challenges to develop advanced neurocritical care exist in LAMICs. 
These are difficult to quantify, given the spectrum across LAMICs, and are best described in a qualitative 
manner. We encourage the use of the highest possible tier of monitoring when applicable to optimize 
the potential benefit from the monitoring. However, we recognize that particular institutional and 
economic circumstances may influence priorities of care and there is a need for flexibility to meet the 
clinical demands under variable constrictions. There should be a balance between desire to establish 
essential monitoring with the notion that there is a valid need for advanced and expert systems given 
the differing sophistication of the various centers, regions and nations. 
Recommendations 
1. We recommend that collaborative multi-center studies are needed to adress the differences in
patients baseline characteristics (Strong recommendation, Moderate quality of evidence).
2. We recommend that comparative studies must control for differences in patient baseline
characteristics and comparison between HICs and LAMICs should be made only where there is
sufficient data about classification, case selection and clinical outcome assessment. (Strong
recommendation, Low quality evidence).
3. We recommend that guidelines for monitoring neurocritical care patients for emerging
economies should consider regional variations and recommendations for monitoring where
these do not currently exist must be carefully considered (Strong recommendation, Moderate
quality evidence).
4. We recommend that ICP monitoring should be used preferably where there is neurocritical care
clinical expertise and in an appropriate intensive care setting. (Strong recommendation,
Moderate quality evidence).
5. We recommend that the role and cost/benefit ratio of MMM in individual LAMICs, and also
HICs, must be weighed against the overall priorities for delivering basic health care at individual
centers (Strong recommendation, Low quality evidence).
Future Directions and Emerging Technologies 
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Multimodality monitoring including clinical and laboratory evaluation, imaging and continuous 
physiologic data is an important feature of neurocritical care. The future appears bright and likely will be 
driven by studies that address the principal limitations to our knowledge, documented in this consensus, 
and by the desire to develop more specific and less invasive brain monitors. It is difficult to demonstrate 
that any single monitor or combination of monitors has a positive effect on outcome, since outcome is 
influenced by the therapeutic plan driven by monitoring, not by monitoring itself. Furthermore, 
information derived from monitors of when and how to treat or how to integrate information from 
various monitors is still being elucidated. Hence, we need to develop more evidence on how various 
monitors used in neurocritical care can influence care and outcome. To that end, small, randomized 
studies that focus on intermediate outcomes or biomarker outcomes seem to be a reasonable approach 
(e.g. 149) although careful observational studies can also help advance understanding of physiology. 
Important enhancements in data display, integration and analysis will be forthcoming as the field of bio-
informatics continues to evolve. However, this will depend on close collaboration between industry, 
engineers, clinicians and regulatory bodies to ensure standardization of device, data element 
terminology and technologies. During the next 5 years, we likely will see the development and 
implementation of several visualization and presentation interfaces that will serve to integrate the data 
into a time-aligned stream of information. Advanced data visualization and interpretation systems, that 
include algorithms to detect: 1) trends in physiological changes (150); 2) autoregulation (45); 3) 
optimum cerebral perfusion pressure (151); 4) patient, rather than population specific thresholds (137); 
5) reasons for physiologic alterations (152) and other predictive methods (153,154) to find the ideal
physiological state for each individual throughout their clinical course, will become commonplace. There 
will be development and validation of several monitors that are currently just being introduced at the 
bedside or are planned, such as next generation NIRS-DCS (155), optic nerve sheath ultrasound (156), 
pupillometry (157), direct current EEG for cortical spreading depolarization (CSD) (158], and TCD-based 
non-invasive measures of ICP [159]. 
Devices used to monitor patients with neurologic disorders are experiencing technological 
advancements leading to high functionality, non-invasive devices, ease of operation, and 
miniaturization. These technologies and others likely will become increasingly used to better monitor 
patients who are at risk of neurological deterioration. The challenge will be to integrate some or all of 
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the multimodality monitors in an organized way to enhance patient care, and to avoid data 
misinterpretation. (160,161) This challenge will likely be met through rigorous training of clinicians with 
expertise in neurocritical care rather than by one or more definitive studies. However multicenter 
collaborative research through careful observation will help understand how care based on monitoring 
impacts outcome including long-term outcome and quality of life after ICU care. In the end, MMM is an 
extension of the clinical exam and cognitive skill set of the clinician, and is only as good or as useful as 
the clinical team who is using the monitor and available therapeutic options.  
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